Invitation to Presentation of BioInvent’s Year-end Report 2023

LUND, SE / ACCESSWIRE / February 20, 2024 / BioInvent International AB("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the year-end report 2023 at 2:00 pm on February 22. The report will be published at 8:00 am CET the same day. BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English. When: Thursday February 22, 2024, at 2:00 pm CET Listen to the presentation webcast: To participate via teleconference, please register via the following link: . Upon registration, a phone number and conference ID for the conference call will be provided. You can ask questions verbally via the telephone conference. The conference call will be made available on the company website after the call. About BioInvent BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at Follow on the social media platform X: @BioInvent. Attachments Invitation to presentation of BioInvent's Year-end report 2023 SOURCE: BioInvent International View the original press release on